MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Advanced Medical Solutions agrees to £715 million takeover by Fuller

ALN

Advanced Medical Solutions Group PLC on Thursday said it has agreed to an all-cash takeover offer from US suitor HB Fuller Co.

The offer of 285 pence per share in cash values the equity of AIM-listed AMS at £659 million and gives an enterprise value, including debt, of £715 million.

AMS shares were up 16% to 278.61p early Thursday in London following the announcement.

HB Fuller shares closed up 2.3% at $64.60 in New York on Wednesday. The stock was down 2.9% in pre-market trade on Thursday. HB Fuller has a market capitalisation of $3.52 billion.

HB Fuller is an adhesives manufacturer based in St Paul, Minnesota. The offer is being made via its wholly owned subsidiary HB Fuller Medical Adhesive Technologies Inc. AMS is a Cheshire, England-based surgical dressings maker.

The US company’s approach to AMS at the end of April was first publicly confirmed in May. Last week, AMS agreed to extend the deadline for HB Fuller to make a firm offer to July 2.

Earlier in May, AMS shares had taken a hit after private equity firm TA Associates (UK) LLP said it didn’t intend to make a takeover offer of its own, having approached AMS about a possible deal in April.

On Thursday, AMS said all of its directors, representing 0.3% of its shares, recommend acceptance of the HB Fuller offer.

Chair Grahame Cook said the deal ‘delivers attractive and certain value in cash to AMS shareholders’.

For its part, HB Fuller Chief Executive Officer Celeste Mastin said: ‘This transaction is a rare opportunity to advance the evolution of our portfolio. We have long been clear that medical is a core strategic growth market for HB Fuller given its durable demand trends, high regulatory-based entry barriers and margin profile.’

Copyright 2026 Alliance News Ltd. All Rights Reserved.